These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22120145)

  • 1. Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
    van Assema DM; Lubberink M; Bauer M; van der Flier WM; Schuit RC; Windhorst AD; Comans EF; Hoetjes NJ; Tolboom N; Langer O; Müller M; Scheltens P; Lammertsma AA; van Berckel BN
    Brain; 2012 Jan; 135(Pt 1):181-9. PubMed ID: 22120145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease.
    Deo AK; Borson S; Link JM; Domino K; Eary JF; Ke B; Richards TL; Mankoff DA; Minoshima S; O'Sullivan F; Eyal S; Hsiao P; Maravilla K; Unadkat JD
    J Nucl Med; 2014 Jul; 55(7):1106-11. PubMed ID: 24842892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
    de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
    Storelli F; Billington S; Kumar AR; Unadkat JD
    Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
    Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
    Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.
    van Assema DM; Goos JD; van der Flier WM; Lubberink M; Boellaard R; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    J Cereb Blood Flow Metab; 2012 Aug; 32(8):1468-71. PubMed ID: 22588188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease.
    Piwnica-Worms D; Kesarwala AH; Pichler A; Prior JL; Sharma V
    Neuroimaging Clin N Am; 2006 Nov; 16(4):575-89, viii. PubMed ID: 17148020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations.
    Chiu C; Miller MC; Monahan R; Osgood DP; Stopa EG; Silverberg GD
    Neurobiol Aging; 2015 Sep; 36(9):2475-82. PubMed ID: 26159621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
    de Klerk OL; Willemsen AT; Bosker FJ; Bartels AL; Hendrikse NH; den Boer JA; Dierckx RA
    Psychiatry Res; 2010 Aug; 183(2):151-6. PubMed ID: 20620031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A(1) receptors using 8-dicyclopropylmethyl-1-[(11)C]methyl-3-propylxanthine PET in Alzheimer's disease.
    Fukumitsu N; Ishii K; Kimura Y; Oda K; Hashimoto M; Suzuki M; Ishiwata K
    Ann Nucl Med; 2008 Dec; 22(10):841-7. PubMed ID: 19142702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration.
    Bartels AL; Kortekaas R; Bart J; Willemsen AT; de Klerk OL; de Vries JJ; van Oostrom JC; Leenders KL
    Neurobiol Aging; 2009 Nov; 30(11):1818-24. PubMed ID: 18358568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene.
    van Assema DM; Lubberink M; Rizzu P; van Swieten JC; Schuit RC; Eriksson J; Scheltens P; Koepp M; Lammertsma AA; van Berckel BN
    EJNMMI Res; 2012 Oct; 2(1):57. PubMed ID: 23067778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
    van Assema DM; van Berckel BN
    Curr Pharm Des; 2016; 22(38):5808-5816. PubMed ID: 27494062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.
    Feldmann M; Asselin MC; Liu J; Wang S; McMahon A; Anton-Rodriguez J; Walker M; Symms M; Brown G; Hinz R; Matthews J; Bauer M; Langer O; Thom M; Jones T; Vollmar C; Duncan JS; Sisodiya SM; Koepp MJ
    Lancet Neurol; 2013 Aug; 12(8):777-85. PubMed ID: 23786896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.
    Takano A; Kusuhara H; Suhara T; Ieiri I; Morimoto T; Lee YJ; Maeda J; Ikoma Y; Ito H; Suzuki K; Sugiyama Y
    J Nucl Med; 2006 Sep; 47(9):1427-33. PubMed ID: 16954549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease?
    Ohtsuki S; Ito S; Terasaki T
    Clin Pharmacol Ther; 2010 Oct; 88(4):443-5. PubMed ID: 20856239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.